NME1 and hepatocellular carcinoma: The clinical performance of AFP, PIVKA-II, and GAAD for detection of early-stage, late-stage, and all-stage HCC at the pre-defined cutoffs are shown in Supplemental Table 5, http://links.lww.com/HC9/A643.